Agilent Zorbax Eclipse AAA - Datasheet

Importance of the Topic

Amino acid profiling is a cornerstone in protein characterization, biopharmaceutical quality control and nutritional analysis. Fast, reliable and reproducible separation of derivatized amino acids enhances throughput in research and industrial laboratories. The Agilent Zorbax Eclipse AAA column addresses these needs by combining advanced stationary-phase technologies with optimized chemistry for rapid, high-resolution analysis of primary and secondary amino acids.

Objectives and Study Overview

This datasheet presents the design, performance and application of the Zorbax Eclipse AAA column. Key objectives include:

• Describing column chemistry and packing characteristics.
• Outlining the optimized protocol for OPA/FMOC derivatization.
• Demonstrating chromatographic performance through batch test data.
• Providing operational guidelines, storage and maintenance recommendations.

Methodology and Instrumentation

Derivatization Protocol:

• Primary amino acids reacted with o-phthalaldehyde (OPA) in the presence of 3-mercaptopropionic acid (3-MPA).
• Secondary amino acids derivatized using 9-fluorenylmethyl chloroformate (FMOC).
• Buffered reaction at pH 10.2 for compatibility with direct injection.

Chromatographic Conditions:

• Reversed-phase separation on Eclipse AAA stationary phase.
• Mobile phases based on water and common organic solvents, pH 3–8.
• Flow direction marked; reverse flow discouraged except for inlet cleaning.

Instrumentation

• Agilent 1100 HPLC system.
• Diode array detector (DAD) with dual-wavelength monitoring or programmed wavelength switching.
• Fluorescence detector for high-sensitivity applications.
• Eclipse AAA guard column and hardware kit for sample protection.

Main Results and Discussion

Batch test chromatograms for a 4.6 × 150 mm, 3.5 µm column demonstrate baseline separation of 20 common amino acids within 10–14 minutes. Uniform, symmetric peaks reflect the doubly endcapped, high-purity silica support. Key observations:

• Primary (OPA) derivatives elute ahead of secondary (FMOC) derivatives due to hydrophobicity differences.
• Excess FMOC byproducts appear after the last amino acid peak, minimizing interference.
• Stable back-pressure up to 400 bar and resistance to dissolution in pH 3–8 mobile phases.

Benefits and Practical Applications

• Rapid turnaround for high-throughput amino acid analysis in protein hydrolysates.
• Compatibility with standard reversed-phase HPLC solvents and buffers.
• Enhanced column lifetime through ultra-pure, eXtraDenseBonding technology and guard column usage.
• Low nonspecific adsorption of basic and polar analytes, ensuring reproducibility.

Future Trends and Applications

• Integration with tandem mass spectrometry for enhanced sensitivity and selectivity.
• Development of sub-2 µm and core–shell variants for ultra-fast separations.
• Automation of derivatization steps on modern, high-throughput platforms.
• Application in process analytical technology (PAT) and real-time quality control.

Conclusion

The Agilent Zorbax Eclipse AAA column offers an optimized solution for efficient, high-resolution amino acid analysis. Its advanced stationary-phase design combined with established OPA/FMOC chemistry supports rapid, reproducible separations essential for research, clinical and industrial laboratories.

References

• Agilent Technologies. Technical Note 5980-1193: Amino Acid Analysis Protocol.